Vanda Pharmaceuticals Announces Presentations at SLEEP 2024

29.05.24 20:17 Uhr

Werte in diesem Artikel

WASHINGTON, May 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2024, to be held in Houston, TX from June 1 through June 5, 2024.

Vanda Logo (PRNewsfoto/Vanda Pharmaceuticals Inc.)

The following will be presented:

June 4, 2024

Presentation Title: "Drug Screening and CRISPR/Cas9 Screening of HCN Channels"
Poster Presentation Session: P-17
Poster Number: 10
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics

Presentation Title: "Melanopsin Crispants in Zebrafish Display Difference in Sleep Latency"
Poster Presentation Session: P-17
Poster Number: 11
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics

Presentation Title: "Genetic Variants Associated with Dim Light Melatonin Onset in a Delayed Sleep-Wake Phase Disorder Cohort"
Poster Presentation Session: P-22
Poster Number: 146
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics

Presentation Title: "Genetic variants associated with TST and LPS in insomnia patients: whole genome sequencing study"
Poster Presentation Session: Late-Breaking Abstracts (LBA); P-31
Poster Number: 451
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics

For more information on SLEEP 2024, please refer to https://www.sleepmeeting.org/

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-presentations-at-sleep-2024-302158424.html

SOURCE Vanda Pharmaceuticals Inc.

Ausgewählte Hebelprodukte auf Vanda Pharmaceuticals

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Vanda Pharmaceuticals

NameHebelKOEmittent
NameHebelKOEmittent
Werbung

Nachrichten zu Vanda Pharmaceuticals IncShs

Analysen zu Vanda Pharmaceuticals IncShs

DatumRatingAnalyst
11.12.2018Vanda Pharmaceuticals PerformOppenheimer & Co. Inc.
04.12.2018Vanda Pharmaceuticals OverweightCantor Fitzgerald
21.09.2018Vanda Pharmaceuticals OutperformOppenheimer & Co. Inc.
19.01.2018Vanda Pharmaceuticals BuySeaport Global Securities
26.05.2017Vanda Pharmaceuticals BuyH.C. Wainwright & Co.
DatumRatingAnalyst
04.12.2018Vanda Pharmaceuticals OverweightCantor Fitzgerald
21.09.2018Vanda Pharmaceuticals OutperformOppenheimer & Co. Inc.
19.01.2018Vanda Pharmaceuticals BuySeaport Global Securities
26.05.2017Vanda Pharmaceuticals BuyH.C. Wainwright & Co.
09.11.2016Vanda Pharmaceuticals BuyAegis Capital
DatumRatingAnalyst
11.12.2018Vanda Pharmaceuticals PerformOppenheimer & Co. Inc.
30.07.2008Vanda Pharmaceuticals DowngradeBanc of America Securities LLC
29.07.2008Vanda Pharmaceuticals DowngradeJP Morgan Chase & Co.
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Vanda Pharmaceuticals IncShs nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"